Medical Product Substitution & Interchangeability Compliance

The contract requires the provision of specialized regulatory expertise to ensure that any substitution of medical products, specifically epinephrine auto-injectors, fully complies with the U.S. Food and Drug Administration’s standards and federal requirements for interchangeability. The focus is on navigating complex regulatory frameworks to validate that substituted products meet the criteria for therapeutic equivalence, labeling accuracy, and safe clinical use under federal guidelines. This includes assessing biopharmaceutical equivalence, managing regulatory documentation, and ensuring alignment with FDA rulings on biosimilars and generic substitutions within the context of federal healthcare systems. The work is executed as a subcontract under the Department of Defense’s Defense Logistics Agency, with the North American Industry Classification System code 541690 indicating it falls under other scientific and technical consulting services. Performance is not tied to a specific geographic location, allowing for remote or nationally distributed support. The contract was posted in July 2026 and is referenced through a unique DLA award identifier, suggesting it is part of a broader procurement effort to secure regulatory compliance for critical medical devices used in military and federal healthcare contexts. Compliance with these standards is essential to maintain continuity of care and legal accountability for life-saving medication substitutions.